P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about orforglipron as a potential treatment for adults with obesity or overweight, regulatory submission and action timing, and the timeline for future readouts, presentations, and other milestones relating to orforglipron and its clinical trials and reflects Lilly's current beliefs and expectations
I am not receiving compensation for it (other than from Seeking Alpha)
Clinical trials have shown that people using Tirzepatide for weight loss have seen significant reductions in body weight between 15% and 22.5% on average over 72 weeks
Pre-freeze the gel packs, place them in the case with a barrier layer between the packs and your medication, and the insulation maintains cold temperatures for a limited window
Negative controls were processed identically but without the primary antibody
However, their use in people with type 1 has surged up 800% between 2008 and 2023